1-6 of 6
Juergen Wolf
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT008: Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100

Grace K. Dy, Ramaswamy Govindan, Vamsidhar Velcheti, Gerald S. Falchook, Antoine Italiano, Juergen Wolf, Adrian G. Sacher, Toshiaki Takahashi, Suresh S. Ramalingam, Christophe Dooms, Dong-Wan Kim, Alfredo Addeo, Jayesh Desai, Martin Schuler, Pascale Tomasini, Qui Tran, Simon Jones, Agnes Ang, Abraham Anderson, Antreas A. Hindoyan, David S. Hong, Bob T. Li
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT008.
https://doi.org/10.1158/1538-7445.AM2022-CT008
Published: 15 June 2022
View article titled, Abstract CT008: Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100
Journal Articles

Abstract CT558: Capmatinib vs docetaxel as second- or third-line therapy in patients with locally advanced or metastatic METex14-mutated NSCLC: The GeoMETry-III trial

Pierre Jean Souquet, Sang-We Kim, Johan F. Vansteenkiste, Anna Robeva, Aline Jary, Sabine Glaser, Alejandro Yovine, Juergen Wolf
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT558.
https://doi.org/10.1158/1538-7445.AM2022-CT558
Published: 15 June 2022
View article titled, Abstract CT558: Capmatinib vs docetaxel as second- or third-line therapy in patients with locally advanced or metastatic <em>MET</em>ex14-mutated NSCLC: The GeoMETry-III trial
Journal Articles

Abstract LB056: Accurate detection of MET exon 14 skipping using a liquid biopsy assay in NSCLC patients in the GEOMETRY mono-1 study

Rebecca S. Heist, Edward B. Garon, Daniel S. Tan, Harry J. Groen, Takashi Seto, Egbert F. Smit, Mike Zou, Yiqun Yang, Ying Li, Andrea Chassot Agostinho, Juergen Wolf
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): LB056.
https://doi.org/10.1158/1538-7445.AM2021-LB056
Published: 01 July 2021
View article titled, Abstract LB056: Accurate detection of <em>MET</em> exon 14 skipping using a liquid biopsy assay in NSCLC patients in the GEOMETRY mono-1 study
Journal Articles

Abstract CT082: Capmatinib in METex14-mutated (mut) advanced non-small cell lung cancer (NSCLC): Results from the phase II GEOMETRY mono-1 study, including efficacy in patients (pts) with brain metastases (BM)

Edward B. Garon, Rebecca S. Heist, Takashi Seto, Ji-Youn Han, Noemi Reguart, Harry J. Groen, Daniel SW Tan, Toyoaki Hida, Maja J. de Jonge, Sergey V. Orlov, Egbert F. Smit, Pierre-Jean Souquet, Johan Vansteenkiste, Sylvie Le Mouhaer, Anna Robeva, Maeve Waldron-Lynch, Monica Giovannini, Juergen Wolf
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT082.
https://doi.org/10.1158/1538-7445.AM2020-CT082
Published: 15 August 2020
View article titled, Abstract CT082: Capmatinib in <em>MET</em>ex14-mutated (mut) advanced non-small cell lung cancer (NSCLC): Results from the phase II GEOMETRY <em>mono-1</em> study, including efficacy in patients (pts) with brain metastases (BM)
Journal Articles

Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer

Lydia Meder, Philipp Schuldt, Martin Thelen, Anna Schmitt, Felix Dietlein, Sebastian Klein, Sven Borchmann, Kerstin Wennhold, Ignacija Vlasic, Sebastian Oberbeck, Richard Riedel, Alexandra Florin, Kristina Golfmann, Hans A. Schlößer, Margarete Odenthal, Reinhard Buettner, Juergen Wolf, Michael Hallek, Marco Herling, Michael von Bergwelt-Baildon, H. Christian Reinhardt, Roland T. Ullrich
Journal: Cancer Research
Cancer Res (2018) 78 (15): 4270–4281.
https://doi.org/10.1158/0008-5472.CAN-17-2176
Published: 31 July 2018
View article titled, Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer
Open the PDF for Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Elevated Serum Levels of CC Thymus and Activation-Related Chemokine (TARC) in Primary Hodgkin's Disease: Potential for a Prognostic Factor

Martin R. Weihrauch, Oliver Manzke, Marc Beyer, Heinz Haverkamp, Volker Diehl, Heribert Bohlen, Juergen Wolf, Joachim L. Schultze
Journal: Cancer Research
Cancer Res (2005) 65 (13): 5516–5519.
https://doi.org/10.1158/0008-5472.CAN-05-0100
Published: 01 July 2005
View article titled, Elevated Serum Levels of CC Thymus and Activation-Related Chemokine (TARC) in Primary Hodgkin's Disease: Potential for a Prognostic Factor
Open the PDF for Elevated Serum Levels of CC Thymus and Activation-Related Chemokine (TARC) in Primary Hodgkin's Disease: Potential for a Prognostic Factor in another window